BPC-157
10 mg vial, 60 capsules
What is SLU-PP-332, in one line? A lab-made small molecule that switches on all three estrogen-related receptors, ERR alpha, beta and gamma, which are the cellular controls that build new mitochondria once endurance training begins. Thomas Burris's group at Saint Louis University created it, and in their mice it lengthened running endurance and cut fat mass. Nobody has given it to a human, and, whatever some catalogues imply, it is not a peptide.
Put the label slu pp 332 peptide to one side, because the chemistry does not support it. There is not a single amino acid in SLU-PP-332. Chemists classify it as an acyl hydrazone, assembled from 4-hydroxybenzoic hydrazide and 2-naphthaldehyde. Its formula is C18H14N2O2, its molecular weight sits at about 290 and its CAS number is 303760-60-3. Set that against MOTS-c, a 16-residue peptide that weighs roughly seven times as much. The letters SLU simply stand for Saint Louis University, home of the Burris lab when the compound was designed.
Why, then, does it sit in peptide shops? Because the scientists who study it overlap heavily with those who study mitochondrial and metabolic peptides. Grouping it that way makes sense for buyers, though it has led some sellers to borrow peptide wording that does not apply. The distinction has practical weight at the bench. A flat aromatic molecule like this one behaves differently once dissolved, and the usual limiting factor is how well it dissolves, not breakdown by enzymes.
The name misleads here too, since estrogen-related receptors have nothing to do with binding estrogen. ERR alpha, beta and gamma are orphan nuclear receptors. They govern the genes behind mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle, and skeletal muscle relies on them to adjust to aerobic training. A drug that activates them is therefore an obvious candidate for an exercise mimetic.
SLU-PP-332 acts on all three ERRs, which makes it a pan-agonist, and it is most potent at ERR alpha. The Burris team found that its boost to exercise capacity relied on ERR alpha in particular. That sets it apart from other exercise mimetic routes, for example AMPK, which AICAR activates directly and MOTS-c indirectly, or PPAR delta.
Only a handful of papers report efficacy, every one from Burris and his collaborators, and every one in cells or mice.
Does SLU-PP-332 work, then? For the outcomes measured in mice, the answer is yes. Beyond that, the data run out.
There is no published human study of SLU-PP-332, and when this page was written ClinicalTrials.gov held no registered trial for it. The University of Florida, where Burris is now based, reported the metabolic syndrome results in 2023 and named the next stages as reshaping the molecule into a drug candidate and running more animal work. Human trials were not on that list.
Where the lab went next is revealing. In 2026 a JPET paper presented SLU-PP-915, a structurally different ERR pan-agonist, and said plainly that SLU-PP-332 lacks oral bioavailability. The mouse work had delivered SLU-PP-332 by intraperitoneal injection. Anyone planning an oral-route study with the capsules should take note, since the developers themselves consider oral exposure poor, so exposure needs to be measured, not assumed.
Questions about slu pp 332 side effects have one straight answer. In people, they are unknown. In the mouse metabolic study, the authors saw no severe side effects. No formal toxicology package, human pharmacokinetic data or long-term animal safety study has been published.
The biology flags some open questions. ERRs are very active in heart muscle, kidney and brown fat, tissues that burn a lot of energy, and nobody has reported what years of pushing those receptors would do. Because energy expenditure and fat oxidation rise, body temperature and food intake are worth logging in any animal study. Our take is that SLU-PP-332 is a useful probe for ERR biology and should be handled as such, not as a ready-made exercise pill.
No approved medicine anywhere contains SLU-PP-332, Australia included, and the compound has no ARTG entry. Consult the current Poisons Standard before any use outside a laboratory. AminoLab supplies it to research labs only, to adults 18 and over. It is not for people or animals, and you will find no dosing advice on this page.
Both formats are on a single product page, our SLU-PP-332 research listing, where you can order online a 5 mg lyophilised vial or a bottle of 60 capsules at 250 mcg each. An independent laboratory tests every lot, and the lot number printed on the vial or bottle links to its report through the COA lookup. The methods are described on our quality testing page.
Vial or capsules? Choose the vial if you are replicating the published mouse studies, and read our capsules versus vial comparison before settling on the bottle. Local shops do not carry it, so we ship it from Australian stock to labs in every state. Plenty of groups add MOTS-c or SS-31 as a mitochondrial comparison arm alongside the ERR agonist.
No. It is a small synthetic molecule, formula C18H14N2O2 and molecular weight around 290, containing no amino acids at all. Structurally it is an acyl hydrazone that activates the estrogen-related receptors. Peptide suppliers carry it because it is studied next to mitochondrial and metabolic peptides like MOTS-c.
Not in people, as no human has received it in a study. The mouse papers recorded no severe side effects. There is still no formal toxicology or long-term safety work, and long exposure effects on energy-hungry tissues like the heart and kidney remain unexamined.
Not so far. Every published result comes from cells or mice in work led by Thomas Burris and colleagues. When this page was written ClinicalTrials.gov showed no registered human trial, and the group's recent papers centre on a newer compound, SLU-PP-915.
Its own developers say it lacks oral bioavailability. A 2026 JPET paper from the Burris lab states this, the mouse studies used intraperitoneal injection, and the same paper offered SLU-PP-915 as an orally active successor. Oral-route designs should therefore measure exposure directly.
Yes, for lab research only. AminoLab ships it from Australian stock as a 5 mg vial or a bottle of 60 capsules, and each lot has an independent certificate. It is not an approved medicine and has no ARTG listing, so check the current Poisons Standard before any use outside a laboratory. Nothing we sell is for human or veterinary use.
10 mg vial, 60 capsules
50 mg vial, 100 mg vial
10 mg vial
3 mL, 3 mL + 1 syringe, 10 mL, 10 mL + 1 syringe, 30 mL, 30 mL + 1 syringe
Research use onlyAminoLab supplies research compounds for laboratory and in-vitro use, not for human or animal consumption. By continuing you confirm you are 18 or older and buying for research.
Leave